|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:advertising
|
collaborative research
global expansion
patient access initiatives
therapeutic innovation
|
|
gptkbp:awards
|
Best_Biotech_Company_2020
|
|
gptkbp:businessModel
|
research and development
product development
licensing agreements
partnerships and collaborations
|
|
gptkbp:CEO
|
gptkb:Samarth_Kulkarni
|
|
gptkbp:clinicalTrials
|
gptkb:Asia
gptkb:United_States
Europe
gene therapies
Phase 1/2
|
|
gptkbp:collaborations
|
gptkb:CureVac
gptkb:Harvard_University
gptkb:Regeneron_Pharmaceuticals
gptkb:MIT
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:focus
|
gene editing
|
|
gptkbp:founded
|
2013
|
|
gptkbp:founder
|
gptkb:Emmanuelle_Charpentier
|
|
gptkbp:funding
|
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:National_Institutes_of_Health
|
|
gptkbp:headquarters
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CRISPR Therapeutics
|
|
gptkbp:investmentFocus
|
October 2016
$300 million
|
|
gptkbp:market
|
approximately $1 billion
|
|
gptkbp:partnerships
|
gptkb:University_of_California,_Berkeley
|
|
gptkbp:patentCitation
|
CRISPR technology
|
|
gptkbp:platforms
|
CRISPR gene editing
|
|
gptkbp:products
|
gptkb:CTX110
CTX001
CTX120
CTX130
|
|
gptkbp:publications
|
clinical outcomes
CRISPR technology advancements
gene editing research
therapeutic applications of CRISPR
safety and efficacy studies
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
EMA
|
|
gptkbp:research_areas
|
genetic diseases
|
|
gptkbp:research_focus
|
cancer
autoimmune diseases
sickle cell disease
beta-thalassemia
|
|
gptkbp:stockExchange
|
NASDAQ:_CRSP
|
|
gptkbp:technology
|
CRISPR-Cas9
|